Ms Hewitt is a member of the board of Melrose Industries plc, UK,
where she chairs the audit committee and is also a member of the board
of National Grid plc. Ms Hewitt also serves as an external member of
the House of Lords Commission, UK, where she also chairs the audit committee.
Ms Hewitt has in her executive career worked for Arthur Andersen
& Co., Gartmore Investment Management Ltd, UK, Citicorp Venture
Capital (now CVC), 3i Group and Smith & Nephew plc, UK.
Ms Hewitt was first elected to the Board of Novo Nordisk A/S in 2012
and has most recently been re-elected in March 2020. Her term as a
board member expires in March 2021.
In March 2020, the Board of Directors of Novo Nordisk A/S assessed
that Ms Hewitt is regarded as an independent board member as defined
in Section 3.2.1 of the Recommendations on Corporate Governance
designated by Nasdaq Copenhagen.
Ms Hewitt became a member of the Audit Committee at Novo Nordisk
A/S in March 2012 and chair of the Audit Committee in March 2015. In
March 2020 the Board of Directors of Novo Nordisk A/S designated Ms
Hewitt as financial expert as defined by the US Securities and
Exchange Commission (SEC) and assessed that Ms Hewitt qualifies as
independent pursuant to the US Securities Exchange Act. In addition,
the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt
has competences in accounting and auditing as required by the Danish
Act on Approved Auditors and Audit Firms.
Ms Hewitt became a member of the Remuneration Committee at Novo
Nordisk A/S in March 2018.
In January 2020 the Board of Directors assessed that the special
competencies possessed by Ms Hewitt that are important for the
performance of her duties are her extensive experience within the
field of medical devices, significant financial knowledge, including
mergers and acquisitions, and knowledge about how large international
Ms Hewitt is a UK national, born November 1956.